<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-125404</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals</dc:title>
<dc:description xml:lang="en">Introduction Prevalence of hyperandrogenism (HA), including the polycystic ovary syndrome (PCOS), in female-to-male transsexuals (FMT) is high. This has been related to metabolic syndrome (MS), which appears to increase cardiovascular morbidity and mortality throughout cross-sex hormone (CSH) therapy. Objectives To assess the prevalence of HA and PCOS in FMT patients before the start of CSH therapy, and their association to MS and its components, insulin resistance (IR) and other cardiovascular risk (CVR) factors. Materials and methods Seventy-seven FMTs underwent clinical and biochemical assessment for HA before the start of CSH therapy. CVR, IR, and other MS parameters were also assessed. Results Prevalence of HA was 49.4% (73.7% were cases of PCOS [Rotterdam criteria]), and prevalence of PCOS in the overall sample was 36.4%. Prevalence of MS was (..) (AU)</dc:description>
<dc:creator>Asenjo Araque, Nuria</dc:creator>
<dc:creator>Becerra-Fernández, Antonio</dc:creator>
<dc:creator>Rodríguez-Molina, José Miguel</dc:creator>
<dc:creator>Aguilar Vilas, María Victorina</dc:creator>
<dc:creator>Menacho Román, Miriam</dc:creator>
<dc:creator>Lucio Pérez, María Jesús</dc:creator>
<dc:creator>Pérez-López, Gilberto</dc:creator>
<dc:creator>Berrocal Sertucha, María Carmen</dc:creator>
<dc:creator>Martín-Lazaro, Juan F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción La prevalencia de hiperandrogenismo (HA), que incluye el síndrome de ovario poliquístico (SOP), es alta en los pacientes transexuales de mujer a hombre (TMH). Este hecho se ha relacionado con el síndrome metabólico (SM), lo que parece aumentar la morbimortalidad cardiovascular a lo largo del tratamiento hormonal cruzado (THC).Objetivos Determinar la prevalencia de HA y SOP en pacientes TMH antes del inicio del THC, y su asociación con el SM y sus componentes, la insulinorresistencia (IR) y otros factores de riesgo cardiovascular (RCV).Materiales y métodos Setenta y siete TMH fueron valorados clínica y analíticamente para HA antes de iniciar el THC. También se determinaron los factores de RCV, la IR y otros parámetros del SM. Resultados La prevalencia de HA fue del 49,4% (el 73,7% de ellos con SOP [criterios de Rotterdam]), y del total de la muestra el 36,4% presentaron SOP. La prevalencia global de SM fue del  (..) (AU)</dc:description>
<dc:source>Endocrinol Nutr;61(7): 351-368, ago.-sept. 2014. tab</dc:source>
<dc:identifier>ibc-125404</dc:identifier>
<dc:title xml:lang="es">Prevalencia de hiperandrogenismo y síndrome de ovario poliquístico en transexuales de mujer a hombre</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d31397^s22080</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d54230^s22074</dc:subject>
<dc:subject>^d10226^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d53386</dc:subject>
<dc:subject>^d36032^s22080</dc:subject>
<dc:subject>^d24542</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d14582</dc:subject>
<dc:type>article</dc:type>
<dc:date>201409</dc:date>
</metadata>
</record>
</ibecs-document>
